Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amela Petty

Physician Assistant, Medical Austin, TX Physician Assistant

NPI 1922344043 CMS profile 10569431

12335 Hymeadow Dr, Suite 150, Austin, TX 78750

Open in the dashboard

General payments

$15,680

806 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amela Petty of Austin, TX is reported in the CMS Open Payments database as having received $15,680 across 806 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,312 107
2024 General $2,416 114
2023 General $2,935 178
2022 General $5,764 281
2021 General $2,253 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amela Petty
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Amela Petty were reported at $2,312. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Amela Petty Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,253 $156 $41–$563 $132
2022 $5,764 $185 $55–$649 $149
2023 $2,935 $199 $58–$717 $160
2024 $2,416 $206 $62–$740 $164
2025 $2,312 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $6,221 450 payments
  2. Relievant Medsystems, Inc. $2,462 21 payments
  3. Spinal Simplicity, LLC $1,373 46 payments
  4. Collegium Pharmaceutical, Inc. $759 39 payments
  5. AbbVie, Inc. $582 31 payments
  6. Protega Pharmaceutials LLC $467 27 payments
  7. Boston Scientific Corporation $456 11 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $405 23 payments
  9. Medtronic, Inc. $337 15 payments
  10. Pfizer Inc. $320 19 payments
  11. Other $2,298 124 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,967 799 payments
  2. Travel and Lodging $1,713 7 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM $3,190 286 payments
  2. Intracept Pain $2,483 21 payments
  3. Intracept Pain $1,875 11 payments
  4. HA MINUTEMAN G3-R $1,373 46 payments
  5. Proclaim IPG $855 56 payments
  6. BELBUCA $604 30 payments
  7. Intracept Pain $563 9 payments
  8. Intracept Pain $563 9 payments
  9. Intracept Pain $563 9 payments
  10. ROXYBOND $467 27 payments
  11. Other $7,356 384 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,738

Median for Physician Assistant: 241

Drug cost

$71,916

Median for Physician Assistant: $4,110

Branded share of claims

10.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 29 $22,978
Movantik Naloxegol Oxalate Brand 27 $13,237
Buprenorphine Generic 18 $5,459
Pregabalin Generic 200 $5,104
Gabapentin Generic 368 $4,865
Lidocaine Generic 22 $3,282
Diclofenac Sodium Generic 73 $2,871
Tramadol Hcl Generic 281 $2,006
Acetaminophen-Codeine Acetaminophen With Codeine Brand 90 $1,620
Naloxone Hcl Generic 25 $1,394

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$13,545

Medicare's payments for the services billed

Medicare patients

70

Average age 74

Services billed

198

45 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Ischemic heart disease 30%
Depression 26%
Osteoporosis 21%
COPD 20%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $167
$167 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $84
$84 29 —
NURTEC ODT
  • PFIZER INC. $81
$81 — —
Qutenza
  • Averitas Pharma Inc. $42
$42 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

806 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record